Device Trial Radar · NCT05375214
iTBS in Bipolar I Depression
Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Mar 3, 2023
Primary completion
Oct 31, 2023
Study completion Nov 22, 2023
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Baszucki Brain Research Fund; Magnus Medical; University of Texas at Austin
- First posted
- May 16, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multisite, open label pilot study to investigate the efficacy and safety of a novel accelerated intermittent theta-burst stimulation (iTBS) protocol while assessing for changes in neuroimaging biomarkers associated with treatment response.
Conditions
- Bipolar Depression
- Bipolar I Disorder
Interventions
Magnus Transcranial Magnetic Neuromodulation System (MNS) with SAINT®(Stanford Accelerated Intelligent Neuromodulation Therapy)Device
Novel intermittent theta burst stimulation protocol with individualized targets in the brain for stimulation using structural and functional MRI inputs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) ScoreTime frame: baseline and post treatment up to 5 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins
Baltimore, Maryland
University of Texas at Austin
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.